MNG661
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.297
- APICAL_SURFACE+0.215
- KRAS_SIGNALING_DN+0.201
- COAGULATION+0.185
- WNT_BETA_CATENIN_SIGNALING+0.172
- PANCREAS_BETA_CELLS+0.140
- HYPOXIA+0.121
- HEDGEHOG_SIGNALING+0.119
- XENOBIOTIC_METABOLISM+0.051
- SPERMATOGENESIS+0.044
Top 10 suppressed
- PROTEIN_SECRETION-0.515
- MYC_TARGETS_V1-0.506
- OXIDATIVE_PHOSPHORYLATION-0.449
- G2M_CHECKPOINT-0.419
- E2F_TARGETS-0.414
- MTORC1_SIGNALING-0.414
- UV_RESPONSE_DN-0.404
- PI3K_AKT_MTOR_SIGNALING-0.351
- MITOTIC_SPINDLE-0.336
- UNFOLDED_PROTEIN_RESPONSE-0.331
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613808 | — | D | 0.912 |
| 2 | MNG1258 | — | — | 0.895 |
| 3 | SJEPD031_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.891 |
| 4 | MDT-AP-0754 | Med | Medulloblastoma | 0.885 |
| 5 | BS_4W68NV3M | Med | Medulloblastoma | 0.881 |
| 6 | SRR1797298 | — | cohortSC | 0.881 |
| 7 | SRR6013488 | — | cohortA1 | 0.879 |
| 8 | 82978 | EPN | Supratentorial EPN | 0.878 |
| 9 | SRR25617906 | — | B | 0.877 |
| 10 | MNG1230 | — | — | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.297 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.215 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.201 | Remibrutinib | — uncovered |
| COAGULATION | 0.185 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.172 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| HYPOXIA | 0.121 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.119 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.051 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.044 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.039 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.037 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |